I don't doubt your claim of being a surgeon in oncology, but I question your objectivity in claiming the following from your post
" Now lets talk about immunotherapy for a little. The only thing smart enough to keep up with cancer and it's ability to mutate is the immune system. We will never be as smart as it is. One of them main problems if not the main problem is the ability of cancer to shut it down. The original vaccines did not work well enough because even though multiple personalized antigens were given the immune system of the patient was not stimulated. That is why it only worked on a few percent(but boy could it work and be sustained). DCVAX is the only company I have ever seen that deals with this issue. It in essence turns on the immune system even if it is shut off. It not only turns it on but turns it on at it's source."
You cannot possibly claim that NWBO "is the only company I have ever seen that deals with this issue" unless you really have not researched the field of immunotherapy very thoroughly and the many companies and independent labs throughout the world who are working on harnessing the patient's immune system thru many different approaches and DC vaccines such as NWBO is just one of them.
Also you claim in your post " If you look at the way the cancer is attacked in immunotherapy it is so different than targeted therapy, that is why you don't get this sudden(often short lived massive shrinkage)" How can you even claim to say such a thing and you claim to work with anti-PD1 and anti-CTLA4 antibody treatments. The reason why the scientific (and investment) community is so excited by these two targeted treatments is that THERE is BOTH dramatic tumor shrinkage AND DURABLE response in those 25-50% who do respond (though the side effects can be dangerous) and this is seen without the need of any cancer vaccine.
"Fighting cancer with our immune system is the only way, I know it. I will try and write a little more about my thoughts on immunotherapy as the days go on. I am an call and am getting called to the OR. I really do hope I am helping and not wasting anyones time. I really believe you cannot make this too complicated, the big picture should tell you what the right direction is."
I agree with you on this one but I question that NWBO is going the right direction with their DIRECT trial and after listening to Dr. Bosch's latest presentation at the ASCO I again question the choices he and the company is making especially considering that he is an immunologist who should be aware of the work of his colleagues in his field from both the science aspect and business viability of that direction. As I suspected early on that their initial Direct protocol was a long shot and it was confirmed by what they saw in a limited response seen early in the trial, they were forced to try to salvage that trial by trying a "new" DC activation protocol that seemed to produce better results using THEIR handpicked metrics. I am hugely disappointed that they failed to reveal what that new protocol was since it doesn't allow another scientist or lab to try to recreate or analyze its potential or advance it (I do understand the need to protect intellectual property, but this is the ASCO. Scientists tend to scrutinize or even dismiss any claims of using a "SPECIAL" product that produces wondrous results. If it produced such wondrous results but you don't want to reveal what that product is then just keep that results to your self and stop trying to advertize your company by paying for this spotlight. And I also agree w/ Pyrr. I had hoped for some ORR data for each indication. Even SD and duration for EACH indication. But instead I get a clumped up grouping of all the patients from different disease indications into two grps method A vs method B (B for better). Survival is VERY important but as Pyrr (and I have also stated) it needs a comparator arm and using a clumped up grouping of patients into a method A vs method B is really not the best way to do this. Maybe they will in a pII trial look at EACH indication, but they could have done the same with their current data in this pI trial- but they didn't and it was their choice not to. I give my hands up to this company for really not making things transparent (again).
News 
Market Data 
Discover 
AI
